The US’s first all biosimilar patent suit shows new pharma IP landscape is emerging
Coherus launched Delaware action against Amgen in what is likely to become an increasingly familiar life sciences litigation scenario.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.